ORLANDO, Fla.--(BUSINESS WIRE)--In an investigational study, Merck’s medicine COZAAR (losartan potassium tablets) 150 mg, administered once daily, significantly reduced the risk of all-cause death or hospitalization due to heart failure compared to a lower 50 mg once daily dose of COZAAR. The Merck-sponsored study compared the safety and efficacy of two doses of COZAAR® in patients with chronic heart failure and reduced cardiac function (left ventricular ejection fraction) who were intolerant of angiotensin-converting enzyme (ACE) inhibitors. The results of the study, called HEAAL -- Heart failure Endpoint evaluation of the A-II-Antagonist Losartan -- were presented by researchers during a late breaking clinical trial session at the American Heart Association (AHA) Scientific Sessions 2009.
